NCT05048901 2026-04-09
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
Clinical Trials
31 trialsNCT06807437 2026-03-31
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Phase 3 Recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT03946527 2026-03-02
LAMPARA
Columbia University
Phase 2 Active not recruiting
NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT00353496 2025-03-05
CLARINET
Ipsen
Phase 3 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03043664 2023-06-29
PLANET
Duke University
Phase 1/2 Completed
NCT02288377 2023-01-18
REMINET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Terminated
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT02683941 2022-07-06
SPINET
Ipsen
Phase 3 Terminated
NCT01861717 2021-09-30
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
Phase 4 Terminated
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02823691 2021-06-07
MetNET-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase EARLY_PHASE1 Unknown
NCT00216372 2020-11-05
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Phase 3 Completed
NCT00326469 2020-11-05
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Ipsen
Phase 2 Completed
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT04065165 2020-02-05
TELEFIRST
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Withdrawn
NCT00681187 2019-11-22
SAPHE
Ipsen
Phase 4 Completed
NCT01313273 2019-11-22
POSEIDON
Ipsen
Phase 3 Terminated
NCT02075606 2019-06-07
CALM-NET
Ipsen
Phase 4 Completed
NCT03083210 2019-05-20
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Samsung Medical Center
Phase 4 Unknown
NCT03439709 2018-03-01
MERGE
Samsung Medical Center
Phase 3 Unknown
NCT02351128 2017-10-18
PHRC-Merkel
University Hospital, Grenoble
Phase 2 Completed
NCT01731925 2017-01-31
SUNLAND
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT00495846 2009-08-17
SS-HCC
Federico II University
Phase 2/3 Completed
NCT00627796 2008-03-03
ATG1line
Federico II University
Phase 4 Completed